Decoding HER2 mutations and overexpression in NSCLC
Patients with advanced non-small cell lung cancer (NSCLC) driven by HER2 mutations or HER2 overexpression continue to experience aggressive disease behavior and poor outcomes. Key challenges persist, including accurately identifying HER2 aberrations, navigating treatment efficacy and toxicity, and managing the high incidence of brain metastases.
As novel HER2-targeted therapies—such as antibody-drug conjugates (ADCs), tyrosine kinase inhibitors (TKIs), and emerging combination strategies—offer more targeted treatment options, timely integration of these options into clinical practice is essential to improve patient survival and quality of life.
This program will strengthen your competency in HER2 biomarker testing to ensure accurate detection and patient selection for targeted treatments, while providing practical guidance to increase your confidence in implementing HER2-targeted therapies in NSCLC, including educational resources to expand your knowledge of their efficacy and safety in patients with brain metastases.
Whats next?
Case
navigator
Apply evidence directly to patient care.
- 2 x 15 min accredited real-world case scenarios
- 0.25 AMA PRA Category 1 Credits™ each
Experts in
conversation
Overcome challenges to implement knowledge into practice.
- 3 x 20 min interactive expert-to-expert video podcasts
Clinical
aid
Action tools to guide at the point-of-care.
- 2 x concise clinical downloadable resources for practical application
